APO Research
Talk to an analyst

APO RESEARCH · REPORT

Influenza A Virus, H3N2 Subtype Infections Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Influenza A Virus, H3N2 Subtype Infections Drug Market Analysis and Forecast 2026-2032

19 December 2025207 pages

Choose your research edition.

Industry ResearchInfluenza A Virus, H3N2 Subtype Infections Drug Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenza A Virus, H3N2 Subtype Infections Drug Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Influenza A Virus, H3N2 Subtype Infections Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenza A Virus, H3N2 Subtype Infections Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenza A Virus, H3N2 Subtype Infections Drug Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Influenza A Virus, H3N2 Subtype Infections Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Influenza A Virus, H3N2 Subtype Infections Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Influenza A Virus, H3N2 Subtype Infections Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Influenza A Virus, H3N2 Subtype Infections Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Influenza A Virus, H3N2 Subtype Infections Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Influenza A Virus, H3N2 Subtype Infections Drug include Johnson & Johnson, AbbVie Inc, Zydus Cadila Healthcare Limited, Visterra, Inc., VBI Vaccines Inc., Sarepta Therapeutics, Inc., OPKO Health, Inc., NanoViricides, Inc. and Mucosis B.V., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Influenza A Virus, H3N2 Subtype Infections Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Influenza A Virus, H3N2 Subtype Infections Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Influenza A Virus, H3N2 Subtype Infections Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Influenza A Virus, H3N2 Subtype Infections Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Influenza A Virus, H3N2 Subtype Infections Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Influenza A Virus, H3N2 Subtype Infections Drug sales, projected growth trends, production technology, application and end-user industry.

Influenza A Virus, H3N2 Subtype Infections Drug Segment by Company

Johnson & Johnson

AbbVie Inc

Zydus Cadila Healthcare Limited

Visterra, Inc.

VBI Vaccines Inc.

Sarepta Therapeutics, Inc.

OPKO Health, Inc.

NanoViricides, Inc.

Mucosis B.V.

MedImmune, LLC

Medicago Inc.

Inovio Pharmaceuticals, Inc.

ILiAD Biotechnologies, LLC

Glide Pharmaceutical Technologies Limited

FluGen, Inc.

Celltrion, Inc.

Aphios Corporation

AIMM Therapeutics B.V.

Influenza A Virus, H3N2 Subtype Infections Drug Segment by Type

NVINF-1

NSC-61610

NP-025

NEO-8877

Others

Influenza A Virus, H3N2 Subtype Infections Drug Segment by Application

Clinic

Hospital

Others

Influenza A Virus, H3N2 Subtype Infections Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza A Virus, H3N2 Subtype Infections Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenza A Virus, H3N2 Subtype Infections Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza A Virus, H3N2 Subtype Infections Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Influenza A Virus, H3N2 Subtype Infections Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Influenza A Virus, H3N2 Subtype Infections Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Influenza A Virus, H3N2 Subtype Infections Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. NVINF-1 Major Manufacturers Table 3. NSC-61610 Major Manufacturers Table 4. NP-025 Major Manufacturers Table 5. NEO-8877 Major Manufacturers Table 6. Others Major Manufacturers Table 7. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Clinic Major Manufacturers Table 9. Hospital Major Manufacturers Table 10. Others Major Manufacturers Table 11. Influenza A Virus, H3N2 Subtype Infections Drug Industry Trends Table 12. Influenza A Virus, H3N2 Subtype Infections Drug Industry Drivers Table 13. Influenza A Virus, H3N2 Subtype Infections Drug Industry Opportunities and Challenges Table 14. Influenza A Virus, H3N2 Subtype Infections Drug Industry Restraints Table 15. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Region (2021-2026) Table 19. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Region (2027-2032) Table 20. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 21. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Region (2021-2026) & (K Units) Table 22. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Region (2027-2032) & (K Units) Table 23. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Region (2021-2026) Table 24. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Region (2027-2032) Table 25. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Manufacturers (2021-2026) Table 29. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 30. Global Influenza A Virus, H3N2 Subtype Infections Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Influenza A Virus, H3N2 Subtype Infections Drug Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Influenza A Virus, H3N2 Subtype Infections Drug Manufacturers, Product Type & Application Table 33. Global Influenza A Virus, H3N2 Subtype Infections Drug Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Influenza A Virus, H3N2 Subtype Infections Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Type (2021-2026) Table 40. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Type (2027-2032) Table 41. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 42. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2026) & (K Units) Table 43. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2027-2032) & (K Units) Table 44. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Type (2021-2026) Table 45. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Type (2027-2032) Table 46. Global Influenza A Virus, H3N2 Subtype Infections Drug Price by Type (2021-2026) & (US$/Unit) Table 47. Global Influenza A Virus, H3N2 Subtype Infections Drug Price by Type (2027-2032) & (US$/Unit) Table 48. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Application (2021-2026) Table 52. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Application (2027-2032) Table 53. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 54. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2026) & (K Units) Table 55. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2027-2032) & (K Units) Table 56. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Application (2021-2026) Table 57. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Application (2027-2032) Table 58. Global Influenza A Virus, H3N2 Subtype Infections Drug Price by Application (2021-2026) & (US$/Unit) Table 59. Global Influenza A Virus, H3N2 Subtype Infections Drug Price by Application (2027-2032) & (US$/Unit) Table 60. Johnson & Johnson Company Information Table 61. Johnson & Johnson Business Overview Table 62. Johnson & Johnson Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 63. Johnson & Johnson Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 64. Johnson & Johnson Recent Development Table 65. AbbVie Inc Company Information Table 66. AbbVie Inc Business Overview Table 67. AbbVie Inc Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. AbbVie Inc Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 69. AbbVie Inc Recent Development Table 70. Zydus Cadila Healthcare Limited Company Information Table 71. Zydus Cadila Healthcare Limited Business Overview Table 72. Zydus Cadila Healthcare Limited Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Zydus Cadila Healthcare Limited Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 74. Zydus Cadila Healthcare Limited Recent Development Table 75. Visterra, Inc. Company Information Table 76. Visterra, Inc. Business Overview Table 77. Visterra, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Visterra, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 79. Visterra, Inc. Recent Development Table 80. VBI Vaccines Inc. Company Information Table 81. VBI Vaccines Inc. Business Overview Table 82. VBI Vaccines Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. VBI Vaccines Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 84. VBI Vaccines Inc. Recent Development Table 85. Sarepta Therapeutics, Inc. Company Information Table 86. Sarepta Therapeutics, Inc. Business Overview Table 87. Sarepta Therapeutics, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Sarepta Therapeutics, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 89. Sarepta Therapeutics, Inc. Recent Development Table 90. OPKO Health, Inc. Company Information Table 91. OPKO Health, Inc. Business Overview Table 92. OPKO Health, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. OPKO Health, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 94. OPKO Health, Inc. Recent Development Table 95. NanoViricides, Inc. Company Information Table 96. NanoViricides, Inc. Business Overview Table 97. NanoViricides, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. NanoViricides, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 99. NanoViricides, Inc. Recent Development Table 100. Mucosis B.V. Company Information Table 101. Mucosis B.V. Business Overview Table 102. Mucosis B.V. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Mucosis B.V. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 104. Mucosis B.V. Recent Development Table 105. MedImmune, LLC Company Information Table 106. MedImmune, LLC Business Overview Table 107. MedImmune, LLC Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. MedImmune, LLC Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 109. MedImmune, LLC Recent Development Table 110. Medicago Inc. Company Information Table 111. Medicago Inc. Business Overview Table 112. Medicago Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Medicago Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 114. Medicago Inc. Recent Development Table 115. Inovio Pharmaceuticals, Inc. Company Information Table 116. Inovio Pharmaceuticals, Inc. Business Overview Table 117. Inovio Pharmaceuticals, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Inovio Pharmaceuticals, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 119. Inovio Pharmaceuticals, Inc. Recent Development Table 120. ILiAD Biotechnologies, LLC Company Information Table 121. ILiAD Biotechnologies, LLC Business Overview Table 122. ILiAD Biotechnologies, LLC Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. ILiAD Biotechnologies, LLC Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 124. ILiAD Biotechnologies, LLC Recent Development Table 125. Glide Pharmaceutical Technologies Limited Company Information Table 126. Glide Pharmaceutical Technologies Limited Business Overview Table 127. Glide Pharmaceutical Technologies Limited Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Glide Pharmaceutical Technologies Limited Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 129. Glide Pharmaceutical Technologies Limited Recent Development Table 130. FluGen, Inc. Company Information Table 131. FluGen, Inc. Business Overview Table 132. FluGen, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. FluGen, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 134. FluGen, Inc. Recent Development Table 135. Celltrion, Inc. Company Information Table 136. Celltrion, Inc. Business Overview Table 137. Celltrion, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Celltrion, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 139. Celltrion, Inc. Recent Development Table 140. Aphios Corporation Company Information Table 141. Aphios Corporation Business Overview Table 142. Aphios Corporation Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Aphios Corporation Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 144. Aphios Corporation Recent Development Table 145. AIMM Therapeutics B.V. Company Information Table 146. AIMM Therapeutics B.V. Business Overview Table 147. AIMM Therapeutics B.V. Influenza A Virus, H3N2 Subtype Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. AIMM Therapeutics B.V. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio Table 149. AIMM Therapeutics B.V. Recent Development Table 150. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2021-2026) & (US$ Million) Table 151. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2027-2032) & (US$ Million) Table 152. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2026) & (K Units) Table 153. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2027-2032) & (K Units) Table 154. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 155. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 156. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2021-2026) & (US$ Million) Table 157. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2027-2032) & (US$ Million) Table 158. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2026) & (K Units) Table 159. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2027-2032) & (K Units) Table 160. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 161. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 162. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 163. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 164. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 165. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 166. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2026) & (K Units) Table 167. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2027-2032) & (K Units) Table 168. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 169. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 170. United States Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 171. Canada Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 172. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2021-2026) & (US$ Million) Table 173. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2027-2032) & (US$ Million) Table 174. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2026) & (K Units) Table 175. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2027-2032) & (K Units) Table 176. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 177. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 178. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2021-2026) & (US$ Million) Table 179. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2027-2032) & (US$ Million) Table 180. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2026) & (K Units) Table 181. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2027-2032) & (K Units) Table 182. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 183. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 184. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 185. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 186. Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 187. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 188. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2026) & (K Units) Table 189. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2027-2032) & (K Units) Table 190. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 191. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 192. Germany Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 193. France Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 194. U.K. Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 195. Italy Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 196. Netherlands Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 197. China Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2021-2026) & (US$ Million) Table 198. China Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2027-2032) & (US$ Million) Table 199. China Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2026) & (K Units) Table 200. China Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2027-2032) & (K Units) Table 201. China Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 202. China Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 203. China Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2021-2026) & (US$ Million) Table 204. China Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2027-2032) & (US$ Million) Table 205. China Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2026) & (K Units) Table 206. China Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2027-2032) & (K Units) Table 207. China Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 208. China Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 209. Asia Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2021-2026) & (US$ Million) Table 210. Asia Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2027-2032) & (US$ Million) Table 211. Asia Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2026) & (K Units) Table 212. Asia Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2027-2032) & (K Units) Table 213. Asia Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 214. Asia Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 215. Asia Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2021-2026) & (US$ Million) Table 216. Asia Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2027-2032) & (US$ Million) Table 217. Asia Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2026) & (K Units) Table 218. Asia Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2027-2032) & (K Units) Table 219. Asia Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 220. Asia Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 221. Asia Influenza A Virus, H3N2 Subtype Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 222. Asia Influenza A Virus, H3N2 Subtype Infections Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 223. Asia Influenza A Virus, H3N2 Subtype Infections Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 224. Asia Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 225. Asia Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2026) & (K Units) Table 226. Asia Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2027-2032) & (K Units) Table 227. Asia Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 228. Asia Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 229. Japan Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 230. South Korea Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 231. India Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 232. Australia Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 233. China Taiwan Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 234. Southeast Asia Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 235. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2021-2026) & (US$ Million) Table 236. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2027-2032) & (US$ Million) Table 237. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2026) & (K Units) Table 238. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2027-2032) & (K Units) Table 239. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 240. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 241. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2021-2026) & (US$ Million) Table 242. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2027-2032) & (US$ Million) Table 243. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2026) & (K Units) Table 244. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2027-2032) & (K Units) Table 245. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 246. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 247. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 248. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 249. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 250. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 251. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021-2026) & (K Units) Table 252. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2027-2032) & (K Units) Table 253. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 254. SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 255. Brazil Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 256. Argentina Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 257. Chile Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 258. Colombia Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 259. Peru Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 260. Saudi Arabia Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 261. Israel Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 262. UAE Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 263. Turkey Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 264. Iran Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 265. Egypt Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Table 266. Key Raw Materials Table 267. Raw Materials Key Suppliers Table 268. Influenza A Virus, H3N2 Subtype Infections Drug Distributors List Table 269. Influenza A Virus, H3N2 Subtype Infections Drug Customers List Table 270. Research Programs/Design for This Report Table 271. Authors List of This Report Table 272. Secondary Sources Table 273. Primary Sources List of Figures Figure 1. Influenza A Virus, H3N2 Subtype Infections Drug Image Figure 2. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. NVINF-1 Image Figure 5. NSC-61610 Image Figure 6. NP-025 Image Figure 7. NEO-8877 Image Figure 8. Others Image Figure 9. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size Share 2021 VS 2025 VS 2032 Figure 11. Clinic Image Figure 12. Hospital Image Figure 13. Others Image Figure 14. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue (2021-2032) & (US$ Million) Figure 16. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Region (2021-2032) Figure 19. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales (2021-2032) & (K Units) Figure 20. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 21. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Influenza A Virus, H3N2 Subtype Infections Drug Sales YoY (2021-2032) & (K Units) Figure 23. Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales YoY (2021-2032) & (K Units) Figure 24. China Influenza A Virus, H3N2 Subtype Infections Drug Sales YoY (2021-2032) & (K Units) Figure 25. Asia (Excluding China) Influenza A Virus, H3N2 Subtype Infections Drug Sales YoY (2021-2032) & (K Units) Figure 26. South America, Middle East and Africa Influenza A Virus, H3N2 Subtype Infections Drug Sales YoY (2021-2032) & (K Units) Figure 27. Global Influenza A Virus, H3N2 Subtype Infections Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Influenza A Virus, H3N2 Subtype Infections Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Type (2021-2032) Figure 33. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 34. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Type (2021-2032) Figure 36. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Application (2021-2032) Figure 39. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 40. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Application (2021-2032) Figure 42. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue Share by Type (2021-2032) Figure 43. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Share by Type (2021-2032) Figure 44. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue Share by Application (2021-2032) Figure 45. North America Influenza A Virus, H3N2 Subtype Infections Drug Sales Share by Application (2021-2032) Figure 46. North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue Share by Country (202

Scope & coverage.

Types
  • NVINF-1
  • NSC-61610
  • NP-025
  • NEO-8877
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Johnson & Johnson
  • AbbVie Inc
  • Zydus Cadila Healthcare Limited
  • Visterra, Inc.
  • VBI Vaccines Inc.
  • Sarepta Therapeutics, Inc.
  • OPKO Health, Inc.
  • NanoViricides, Inc.
  • Mucosis B.V.
  • MedImmune, LLC
  • Medicago Inc.
  • Inovio Pharmaceuticals, Inc.
  • ILiAD Biotechnologies, LLC
  • Glide Pharmaceutical Technologies Limited
  • FluGen, Inc.
  • Celltrion, Inc.
  • Aphios Corporation
  • AIMM Therapeutics B.V.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Influenza A Virus, H3N2 Subtype Infections Drug Market by Type
  3. 1.2.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 NVINF-1
  5. 1.2.3 NSC-61610
  6. 1.2.4 NP-025
  7. 1.2.5 NEO-8877
  8. 1.2.6 Others
  9. 1.3 Influenza A Virus, H3N2 Subtype Infections Drug Market by Application
  10. 1.3.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Clinic
  12. 1.3.3 Hospital
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Influenza A Virus, H3N2 Subtype Infections Drug Market Dynamics
  1. 2.1 Influenza A Virus, H3N2 Subtype Infections Drug Industry Trends
  2. 2.2 Influenza A Virus, H3N2 Subtype Infections Drug Industry Drivers
  3. 2.3 Influenza A Virus, H3N2 Subtype Infections Drug Industry Opportunities and Challenges
  4. 2.4 Influenza A Virus, H3N2 Subtype Infections Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region
  3. 3.2.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Region
  9. 3.4.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Manufacturers
  2. 4.1.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Manufacturers
  6. 4.2.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Influenza A Virus, H3N2 Subtype Infections Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Influenza A Virus, H3N2 Subtype Infections Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Influenza A Virus, H3N2 Subtype Infections Drug Manufacturers, Product Type & Application
  13. 4.7 Global Influenza A Virus, H3N2 Subtype Infections Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Market CR5 and HHI
  16. 4.8.2 2025 Influenza A Virus, H3N2 Subtype Infections Drug Tier 1, Tier 2, and Tier 3
5 Influenza A Virus, H3N2 Subtype Infections Drug Market by Type
  1. 5.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type
  2. 5.1.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type
  6. 5.2.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Price by Type
6 Influenza A Virus, H3N2 Subtype Infections Drug Market by Application
  1. 6.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application
  2. 6.1.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application
  6. 6.2.1 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Influenza A Virus, H3N2 Subtype Infections Drug Price by Application
7 Company Profiles
  1. 7.1 Johnson & Johnson
  2. 7.1.1 Johnson & Johnson Company Information
  3. 7.1.2 Johnson & Johnson Business Overview
  4. 7.1.3 Johnson & Johnson Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Johnson & Johnson Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  6. 7.1.5 Johnson & Johnson Recent Developments
  7. 7.2 AbbVie Inc
  8. 7.2.1 AbbVie Inc Company Information
  9. 7.2.2 AbbVie Inc Business Overview
  10. 7.2.3 AbbVie Inc Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 AbbVie Inc Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  12. 7.2.5 AbbVie Inc Recent Developments
  13. 7.3 Zydus Cadila Healthcare Limited
  14. 7.3.1 Zydus Cadila Healthcare Limited Company Information
  15. 7.3.2 Zydus Cadila Healthcare Limited Business Overview
  16. 7.3.3 Zydus Cadila Healthcare Limited Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Zydus Cadila Healthcare Limited Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  18. 7.3.5 Zydus Cadila Healthcare Limited Recent Developments
  19. 7.4 Visterra, Inc.
  20. 7.4.1 Visterra, Inc. Company Information
  21. 7.4.2 Visterra, Inc. Business Overview
  22. 7.4.3 Visterra, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Visterra, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  24. 7.4.5 Visterra, Inc. Recent Developments
  25. 7.5 VBI Vaccines Inc.
  26. 7.5.1 VBI Vaccines Inc. Company Information
  27. 7.5.2 VBI Vaccines Inc. Business Overview
  28. 7.5.3 VBI Vaccines Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 VBI Vaccines Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  30. 7.5.5 VBI Vaccines Inc. Recent Developments
  31. 7.6 Sarepta Therapeutics, Inc.
  32. 7.6.1 Sarepta Therapeutics, Inc. Company Information
  33. 7.6.2 Sarepta Therapeutics, Inc. Business Overview
  34. 7.6.3 Sarepta Therapeutics, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Sarepta Therapeutics, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  36. 7.6.5 Sarepta Therapeutics, Inc. Recent Developments
  37. 7.7 OPKO Health, Inc.
  38. 7.7.1 OPKO Health, Inc. Company Information
  39. 7.7.2 OPKO Health, Inc. Business Overview
  40. 7.7.3 OPKO Health, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 OPKO Health, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  42. 7.7.5 OPKO Health, Inc. Recent Developments
  43. 7.8 NanoViricides, Inc.
  44. 7.8.1 NanoViricides, Inc. Company Information
  45. 7.8.2 NanoViricides, Inc. Business Overview
  46. 7.8.3 NanoViricides, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 NanoViricides, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  48. 7.8.5 NanoViricides, Inc. Recent Developments
  49. 7.9 Mucosis B.V.
  50. 7.9.1 Mucosis B.V. Company Information
  51. 7.9.2 Mucosis B.V. Business Overview
  52. 7.9.3 Mucosis B.V. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Mucosis B.V. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  54. 7.9.5 Mucosis B.V. Recent Developments
  55. 7.10 MedImmune, LLC
  56. 7.10.1 MedImmune, LLC Company Information
  57. 7.10.2 MedImmune, LLC Business Overview
  58. 7.10.3 MedImmune, LLC Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 MedImmune, LLC Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  60. 7.10.5 MedImmune, LLC Recent Developments
  61. 7.11 Medicago Inc.
  62. 7.11.1 Medicago Inc. Company Information
  63. 7.11.2 Medicago Inc. Business Overview
  64. 7.11.3 Medicago Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Medicago Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  66. 7.11.5 Medicago Inc. Recent Developments
  67. 7.12 Inovio Pharmaceuticals, Inc.
  68. 7.12.1 Inovio Pharmaceuticals, Inc. Company Information
  69. 7.12.2 Inovio Pharmaceuticals, Inc. Business Overview
  70. 7.12.3 Inovio Pharmaceuticals, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Inovio Pharmaceuticals, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  72. 7.12.5 Inovio Pharmaceuticals, Inc. Recent Developments
  73. 7.13 ILiAD Biotechnologies, LLC
  74. 7.13.1 ILiAD Biotechnologies, LLC Company Information
  75. 7.13.2 ILiAD Biotechnologies, LLC Business Overview
  76. 7.13.3 ILiAD Biotechnologies, LLC Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 ILiAD Biotechnologies, LLC Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  78. 7.13.5 ILiAD Biotechnologies, LLC Recent Developments
  79. 7.14 Glide Pharmaceutical Technologies Limited
  80. 7.14.1 Glide Pharmaceutical Technologies Limited Company Information
  81. 7.14.2 Glide Pharmaceutical Technologies Limited Business Overview
  82. 7.14.3 Glide Pharmaceutical Technologies Limited Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Glide Pharmaceutical Technologies Limited Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  84. 7.14.5 Glide Pharmaceutical Technologies Limited Recent Developments
  85. 7.15 FluGen, Inc.
  86. 7.15.1 FluGen, Inc. Company Information
  87. 7.15.2 FluGen, Inc. Business Overview
  88. 7.15.3 FluGen, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 FluGen, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  90. 7.15.5 FluGen, Inc. Recent Developments
  91. 7.16 Celltrion, Inc.
  92. 7.16.1 Celltrion, Inc. Company Information
  93. 7.16.2 Celltrion, Inc. Business Overview
  94. 7.16.3 Celltrion, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Celltrion, Inc. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  96. 7.16.5 Celltrion, Inc. Recent Developments
  97. 7.17 Aphios Corporation
  98. 7.17.1 Aphios Corporation Company Information
  99. 7.17.2 Aphios Corporation Business Overview
  100. 7.17.3 Aphios Corporation Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Aphios Corporation Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  102. 7.17.5 Aphios Corporation Recent Developments
  103. 7.18 AIMM Therapeutics B.V.
  104. 7.18.1 AIMM Therapeutics B.V. Company Information
  105. 7.18.2 AIMM Therapeutics B.V. Business Overview
  106. 7.18.3 AIMM Therapeutics B.V. Influenza A Virus, H3N2 Subtype Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 AIMM Therapeutics B.V. Influenza A Virus, H3N2 Subtype Infections Drug Product Portfolio
  108. 7.18.5 AIMM Therapeutics B.V. Recent Developments
8 North America
  1. 8.1 North America Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Type
  2. 8.1.1 North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Influenza A Virus, H3N2 Subtype Infections Drug Price by Type (2021-2032)
  5. 8.2 North America Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Application
  6. 8.2.1 North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Influenza A Virus, H3N2 Subtype Infections Drug Price by Application (2021-2032)
  9. 8.3 North America Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country
  10. 8.3.1 North America Influenza A Virus, H3N2 Subtype Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Influenza A Virus, H3N2 Subtype Infections Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Type
  2. 9.1.1 Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Influenza A Virus, H3N2 Subtype Infections Drug Price by Type (2021-2032)
  5. 9.2 Europe Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Application
  6. 9.2.1 Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Influenza A Virus, H3N2 Subtype Infections Drug Price by Application (2021-2032)
  9. 9.3 Europe Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country
  10. 9.3.1 Europe Influenza A Virus, H3N2 Subtype Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Influenza A Virus, H3N2 Subtype Infections Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Type
  2. 10.1.1 China Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2032)
  4. 10.1.3 China Influenza A Virus, H3N2 Subtype Infections Drug Price by Type (2021-2032)
  5. 10.2 China Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Application
  6. 10.2.1 China Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2032)
  8. 10.2.3 China Influenza A Virus, H3N2 Subtype Infections Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Type
  2. 11.1.1 Asia Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Influenza A Virus, H3N2 Subtype Infections Drug Price by Type (2021-2032)
  5. 11.2 Asia Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Application
  6. 11.2.1 Asia Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Influenza A Virus, H3N2 Subtype Infections Drug Price by Application (2021-2032)
  9. 11.3 Asia Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country
  10. 11.3.1 Asia Influenza A Virus, H3N2 Subtype Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Influenza A Virus, H3N2 Subtype Infections Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Type
  2. 12.1.1 SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Application
  6. 12.2.1 SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Market Size by Country
  10. 12.3.1 SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Influenza A Virus, H3N2 Subtype Infections Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Influenza A Virus, H3N2 Subtype Infections Drug Value Chain Analysis
  2. 13.1.1 Influenza A Virus, H3N2 Subtype Infections Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Influenza A Virus, H3N2 Subtype Infections Drug Production Mode & Process
  6. 13.2 Influenza A Virus, H3N2 Subtype Infections Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Influenza A Virus, H3N2 Subtype Infections Drug Distributors
  9. 13.2.3 Influenza A Virus, H3N2 Subtype Infections Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst